Rituximab Therapy for Resistant Myasthenia Gravis

The paper presents a single-center prospective cohort study from Latvia examining the use of the anti-CD20 monoclonal antibody, rituximab, as a treatment for refractory myasthenia gravis (MG). Conducted on nine patients who had failed conventional treatments, the study evaluated the effects of a single low dose over a six-month period. Results indicated significant clinical improvement, marked by a decrease in the Myasthenia Gravis Composite Score (MGCS), and the treatment successfully achieved a steroid-sparing effect, reducing the median daily corticosteroid dose for the cohort. The authors highlight that the therapy was notably safe, reporting no severe adverse reactions or episodes of MG exacerbation requiring intensive rescue treatment. While recognizing the small sample size, the study’s findings reinforce that rituximab is a promising addition to the therapeutic options for managing this challenging autoimmune disorder.